인플루엔자 진단 시장 : 제품 유형별, 검사 유형별, 검체 유형별, 기술별, 검사 방법 및 시행 환경별, 대상 질환별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Influenza Diagnostics Market is projected to grow by USD 3.89 billion at a CAGR of 10.80% by 2032.

Influenza diagnostics are moving from episodic seasonal testing toward always-on respiratory infection intelligence. The clinical need is clear: the World Health Organization estimates that seasonal influenza causes about 1 billion infections annually, including 3 to 5 million severe cases and 290,000 to 650,000 respiratory deaths. These figures keep influenza testing central to emergency care, primary care, pediatrics, long-term care, occupational health, and public health surveillance.

The market is shaped by rapid influenza diagnostic tests, molecular assays such as RT-PCR and isothermal amplification, multiplex respiratory panels, point-of-care platforms, and laboratory information systems that connect test results to treatment decisions. Demand is strongest where clinicians need fast differentiation between influenza A, influenza B, SARS-CoV-2, RSV, and other respiratory pathogens to guide antiviral use, isolation, antibiotic stewardship, and hospital capacity planning.

Transformative Shifts in the Influenza Testing Landscape

The most important shift is the move from single-pathogen flu testing to syndromic respiratory diagnostics. During and after the COVID-19 pandemic, health systems accelerated adoption of multiplex assays that detect influenza, SARS-CoV-2, RSV, and other pathogens from one specimen. This has changed purchasing behavior, with laboratories and clinics increasingly prioritizing workflow efficiency, result turnaround time, and clinical actionability over test volume alone.

A second shift is the expansion of point-of-care molecular diagnostics. Traditional rapid antigen tests remain useful because they are inexpensive and can deliver results in minutes, but CDC guidance has long noted that rapid influenza diagnostic tests generally have lower sensitivity than molecular methods. As a result, near-patient molecular platforms are gaining importance in urgent care, emergency departments, pharmacies, and decentralized care settings where speed and accuracy both matter.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer across influenza diagnostics rather than a standalone product category. AI models support outbreak forecasting, test demand planning, laboratory workflow triage, and interpretation of large respiratory surveillance datasets. When linked with electronic health records, syndromic surveillance, weather patterns, mobility indicators, and historical positivity rates, AI can help health systems anticipate testing peaks and allocate reagents, staff, and instruments more efficiently.

AI also strengthens diagnostic operations by improving quality control, automating result review, and flagging unusual positivity patterns that may indicate localized outbreaks or specimen handling issues. The greatest near-term value is expected in decision support: combining test results with symptoms, exposure history, vaccination status, and local influenza activity to guide antiviral prescribing and infection control. Adoption will depend on validation, transparency, cybersecurity, and regulatory alignment.

Key Regional Insights: Global Demand Patterns

North America remains one of the most advanced influenza diagnostics regions due to high laboratory capacity, established CDC and Public Health Agency of Canada surveillance systems, broad use of molecular testing, and strong reimbursement pathways for clinically necessary respiratory testing. Europe benefits from coordinated influenza monitoring through national agencies and ECDC-linked surveillance, with demand supported by hospital networks, primary care sentinel systems, and a strong installed base of laboratory molecular platforms.

Asia-Pacific is a highly dynamic environment because of large population scale, recurring influenza burden, expanding hospital infrastructure, and government investment in infectious disease preparedness after COVID-19 and avian influenza concerns. China, Japan, India, South Korea, Australia, and ASEAN markets are expanding use of rapid and molecular respiratory testing at different speeds depending on reimbursement, access, and local manufacturing capacity.

Latin America, the Middle East, and Africa present rising opportunities as governments strengthen respiratory disease surveillance and decentralized diagnostics. Brazil and Mexico anchor Latin American demand, while GCC health systems invest in advanced hospital diagnostics and digital health. Across Africa, demand is supported by the need for scalable point-of-care testing, but adoption is constrained by affordability, procurement fragmentation, cold-chain logistics, and uneven access to molecular laboratories.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

In ASEAN, influenza diagnostics demand is tied to urban hospital expansion, travel-related surveillance, and the need to monitor overlapping respiratory outbreaks in tropical and subtropical climates where seasonality can be less predictable. The GCC is investing in high-acuity hospital systems, laboratory automation, and health security programs, making multiplex respiratory testing attractive for emergency departments, pilgrimage-related public health planning, and premium care networks.

The European Union supports a mature diagnostics environment through harmonized regulatory expectations, strong laboratory networks, and cross-border disease monitoring. BRICS countries represent high-volume demand because Brazil, Russia, India, China, and South Africa combine large patient populations with growing domestic diagnostics manufacturing and government-led infectious disease programs.

G7 markets are characterized by advanced reimbursement systems, early adoption of molecular and multiplex platforms, and strong clinical guideline influence. NATO countries, while not a healthcare bloc, increasingly view infectious disease readiness as part of resilience planning, supporting demand for diagnostics that can operate reliably across civilian, military, and emergency response settings.

Key Country Insights: Leading Influenza Diagnostics Markets

The United States leads in test menu breadth, point-of-care molecular adoption, and integration of influenza diagnostics with CDC surveillance and health system protocols. Canada emphasizes public health reporting and equitable access across provinces, while Mexico is expanding rapid and molecular respiratory testing through public and private providers. Brazil has strong national surveillance infrastructure and significant demand during Southern Hemisphere influenza seasons.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature demand for laboratory-based molecular testing, hospital respiratory panels, and primary care surveillance. Germany and France benefit from strong laboratory networks; the United Kingdom has advanced public health analytics; Italy and Spain have significant hospital demand during seasonal surges. Russia maintains demand through public sector hospital systems and domestic diagnostics capacity.

In Asia-Pacific, China is a major volume market with expanding molecular testing infrastructure and government focus on respiratory pathogen monitoring. India combines high disease burden with growing private diagnostics chains and a need for affordable rapid testing. Japan and South Korea are advanced adopters of high-quality diagnostics, automation, and surveillance-linked testing. Australia benefits from strong seasonal monitoring, public health reporting, and established use of molecular respiratory assays.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that combine speed, accuracy, and operational simplicity. Product portfolios need to cover both cost-sensitive rapid testing and higher-sensitivity molecular options, with clear positioning by care setting: home and pharmacy screening, urgent care triage, hospital admission testing, and reference laboratory confirmation.

Organizations should invest in multiplex respiratory panels that remain clinically focused and economically defensible. Overly broad panels may face reimbursement scrutiny, while targeted influenza, RSV, and SARS-CoV-2 combinations align closely with real-world clinical decisions. Partnerships with public health agencies, hospital networks, and digital surveillance platforms can strengthen access and demonstrate measurable value.

Manufacturers should also localize strategies by region. In mature markets, differentiation should center on turnaround time, connectivity, automation, and health-economic evidence. In emerging markets, affordability, rugged instruments, simplified procurement, training, and reliable reagent supply are decisive.

Research Methodology for Evidence-Based Analysis

This executive summary is based on secondary research and evidence synthesis from recognized public health and regulatory sources, including WHO influenza burden estimates, CDC diagnostic guidance, ECDC surveillance frameworks, national public health agencies, peer-reviewed literature, and publicly available regulatory information. The analysis emphasizes verified epidemiological patterns, clinical testing practices, technology adoption trends, and regional healthcare infrastructure factors.

The methodology combines qualitative assessment of industry drivers with comparative evaluation of diagnostic modalities, including rapid antigen tests, RT-PCR, isothermal molecular assays, multiplex panels, point-of-care platforms, and digital surveillance tools. Insights were reviewed for consistency with established clinical guidance and current respiratory disease preparedness priorities.

Conclusion: The Future of Influenza Diagnostics

Influenza diagnostics are becoming a strategic component of respiratory care, public health preparedness, and healthcare system efficiency. The field is no longer defined only by seasonal testing activity; it is increasingly shaped by molecular accuracy, multiplex capability, point-of-care deployment, data connectivity, and AI-enabled surveillance.

Organizations that align testing solutions with clinical workflows, reimbursement realities, and regional access needs will be well positioned for durable relevance. As influenza continues to overlap with RSV, COVID-19, and emerging respiratory threats, reliable diagnostics will remain essential for timely treatment, outbreak control, and informed health policy.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Influenza Diagnostics Market, by Product Type

• 7.1. Test Kits & Reagents
  • 7.1.1. RIDT Kits
  • 7.1.2. PCR Reagent Kits
  • 7.1.3. Controls & Calibrators
• 7.2. Instruments / Analyzers
• 7.3. Consumables & Accessories
  • 7.3.1. Swabs
  • 7.3.2. Pipettes
  • 7.3.3. Cartridges
  • 7.3.4. Microplates

8. Influenza Diagnostics Market, by Test Type

• 8.1. Rapid Antigen Tests
  • 8.1.1. Lateral Flow Tests
  • 8.1.2. Immunoassay Tests
• 8.2. Molecular Tests
  • 8.2.1. RT-PCR Singleplex Tests
  • 8.2.2. RT-PCR Multiplex Respiratory Tests
  • 8.2.3. Isothermal Amplification Tests
• 8.3. Serology Tests
  • 8.3.1. IgM Antibody Tests
  • 8.3.2. Total Antibody Tests
  • 8.3.3. IgG Antibody Tests
• 8.4. Reference & Advanced Characterization Tests
  • 8.4.1. Viral Culture-Based Tests
  • 8.4.2. Sequencing-Based Strain Characterization Tests
  • 8.4.3. Subtyping And Surveillance Assays

9. Influenza Diagnostics Market, by Sample Type

• 9.1. Nasopharyngeal Swabs
• 9.2. Bronchoalveolar Lavage (BAL)
• 9.3. Oropharyngeal Swabs
• 9.4. Blood/serum Swabs
• 9.5. Nasal Swabs

10. Influenza Diagnostics Market, by Technology

• 10.1. Immunoassay-Based
  • 10.1.1. Enzyme Immunoassay
  • 10.1.2. Chemiluminescent Immunoassay
• 10.2. Polymerase Chain Reaction
• 10.3. Isothermal Amplification Technologies

11. Influenza Diagnostics Market, by Mode of Testing / Setting

• 11.1. Point-of-Care Testing (POCT)
• 11.2. Laboratory Testing
• 11.3. Home-Based Testing

12. Influenza Diagnostics Market, by Disease Indication

• 12.1. Influenza A
• 12.2. Influenza B
• 12.3. Seasonal Influenza infections
• 12.4. Pandemic / Novel Influenza

13. Influenza Diagnostics Market, by End User

• 13.1. Academic & Research Institutes
• 13.2. Clinics
• 13.3. Diagnostic Laboratories
• 13.4. Hospitals

14. Influenza Diagnostics Market, by Distribution Channel

• 14.1. Direct Sales
• 14.2. Distributors & Wholesalers
• 14.3. Online Medical Platforms

15. Influenza Diagnostics Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Influenza Diagnostics Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Influenza Diagnostics Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. F. Hoffmann-La Roche Ltd.
• 19.3. QuidelOrtho Corporation
• 19.4. Thermo Fisher Scientific
• 19.5. Siemens Healthineers AG
• 19.6. Qiagen N.V.
• 19.7. Becton, Dickinson and Company
• 19.8. Seegene, Inc.
• 19.9. DiaSorin S.p.A.
• 19.10. Hologic, Inc.
• 19.11. Agilent Technologies, Inc.
• 19.12. Bio-Rad Laboratories, Inc.
• 19.13. Guangzhou Wondfo Biotech Co., Ltd.
• 19.14. Cocrystal Pharma, Inc.
• 19.15. Visby Medical, Inc.
• 19.16. Access Bio, Inc.
• 19.17. ACON Laboratories, Inc.
• 19.18. Bioneer Corporation
• 19.19. CSL Limited
• 19.20. GenBody Inc.
• 19.21. Hangzhou AllTest Biotech Co., Ltd.
• 19.22. Jiangsu Bioperfectus Technologies Co., Ltd.
• 19.23. NATCO Pharma Limited
• 19.24. Novacyt S.A.
• 19.25. Novartis AG
• 19.26. R-Biopharm AG
• 19.27. Sansure Biotech Inc.
• 19.28. Shionogi & Co., Ltd.
• 19.29. Teva Pharmaceutical Industries Ltd.
• 19.30. Vircell, S.L.
• 19.31. Zydus Pharmaceuticals, Inc.